Jiong Wu

机构：Shanghai Medical College of Fudan University, Chinese PLA General Hospital, Fudan University Shanghai Cancer Center, Jiangsu Provincial Hospital of Traditional Chinese Medicine · ORCID：0000-0002-8103-0505

发表论文 562 篇 · 总被引 14377 次 · h-index 68

代表论文

• Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial (2025 · Annals of Oncology · 被引 67)
• Interferon-induced senescent CD8 + T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer (2025 · Science Translational Medicine · 被引 22)
• Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial (2025 · Journal of Clinical Oncology · 被引 5)
• Ultrasmall polylysine dendrimer nanodots for glutathione-responsive targeted chemotherapy and enhanced photodynamic/immunotherapy of metastatic cancer (2025 · Chemical Engineering Journal · 被引 5)
• Dihydrotanshinone I Induces Autophagic Cell Death in Ovarian Cancer by Disrupting the SORT1-Mediated Autophagy–Lysosome Pathway (2025 · Engineering · 被引 5)
• Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial (2025 · Cancer Cell · 被引 4)